Recombinant adeno-associated virus (rAAV) vectors are increasingly being used as tools for gene therapy, and clinical trials have begun in patients with genetically linked retinal disorders. Intravitreal injection is optimal for the transduction of retinal ganglion cells (RGCs), although complete selectivity has not been achieved. There may also be advantages in using intravitreal approaches for the transduction of photoreceptors. Here we compared the cellular tropism and transduction efficiency of rAAV2/1, -2/2, -2/3, -2/4, -2/5, -2/6 and -2/8 in adult rat retina after intravitreal injection. Each vector encoded green fluorescent protein (GFP), and the number, laminar distribution and morphology of transduced GFP + cells were determined using fluorescent microscopy. Assessment of transduced cell phenotype was based on cell morphology and immunohistochemistry. rAAV2/2 and rAAV2/6 transduced the greatest number of cells, whereas rAAV2/5 and rAAV2/8 were least efficient. Most vectors primarily transduced RGCs; however, rAAV2/6 had a more diverse tropism profile, with 46% identified as amacrine or bipolar cells, 23% as RGCs and 22% as Mü ller cells. Mü ller cells were also frequently transduced by rAAV2/4. The highest photoreceptor transduction was seen after intravitreal rAAV2/3 injection. These data facilitate the design and selection of rAAV vectors to target specific retinal cells, potentially leading to an improved gene therapy for various human retinal pathologies.
Introduction
Recombinant, replication-deficient adeno-associated virus (rAAV) vectors are increasingly being used in gene therapy trials in the central nervous system. 1 rAAV vectors transduce a variety of cell types while inducing minimal immune responses in the host. 2 In the eye, rAAV has been used in experimental studies aimed at treating retinal degenerative diseases or for cell rescue following trauma. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] On the basis of the success of some of these animal studies, clinical trials with AAV vectors have recently been initiated in humans with genetically linked ophthalmic diseases. 15, 16 Human AAV serotype 2 was originally found as a contaminant in adenovirus preparations 17 and has not been associated with any human pathogenicity. Since then, several other AAV serotypes have been identified with slight variations in amino-acid capsid identity. AAV serotypes 1-8 share about 60% amino-acid capsid homology, [18] [19] [20] [21] [22] the largest amino-acid variations being concentrated to the hypervariable regions exposed on the capsid surface. 23 Variation in capsid structure affects viral tropism and expression kinetics in terms of the onset and expression levels of therapeutic genes, and the use of different serotypes may allow for a more cellspecific gene transfer. 3, 6, 8, 12, 24, 25 Robust photoreceptor transduction has been reported after subretinal injection of many vector types; however, photoreceptors are only infrequently transduced after intravitreal injection of the serotypes tested to date. 3, 4, [6] [7] [8] 11, 12, 26 Intravitreal vector delivery is a less invasive technique compared with subretinal delivery. A larger vector volume can be delivered and this approach also allows repeated injections, and can thus be combined with the delivery of other pharmacotherapeutic agents. 9, 10, [27] [28] [29] [30] [31] The ability to target photoreceptor cells in the outer retina through intravitreal injections may therefore be of clinical benefit.
Retinal ganglion cells (RGCs) are targeted directly by intravitreal injections and gene therapy may be an effective method for rescuing these neurons in degenerative conditions such as glaucoma, ischaemia, optic neuritis and optic neuropathy. 28 rAAV2 vectors transduce RGCs [8] [9] [10] [11] [12] but not with absolute selectivity, 11 which may complicate gene therapy treatment of ophthalmic disease. It is, therefore, important to evaluate the tropism and transduction efficiency of other AAV serotypes to determine if there are even more efficient and specific vectors that target RGCs. In this study, we assessed the cellular tropism and transduction efficiencies of titrematched rAAV2/1, -2/2, -2/3, -2/4, -2/5, -2/6 and -2/8 vectors in adult rat retina after a single intravitreal injection. All vectors encoded the gene for green fluorescent protein (GFP) and possessed an AAV2 backbone, cross-packed into capsids from another serotype, hence the pseudoserotype nomenclature AAV2/capsid serotype. Retinas were analyzed 10 weeks post-injection, a time point at which all vector types should maintain a strong gene expression. 6, 8, 12, 24 For each serotype, the number, morphology and laminar distribution of GFP-positive ( + ) cells were quantified using confocal and fluorescence microscopy. Phenotype was also assessed by double immunolabelling with various markers for retinal cell types.
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Results
Intensity measurements of retinal GFP expression in eyecups rAAV titres were matched for each serotype group (4 ml eye injections, 2.6 Â 10 9 genomic counts per injection). In each group, there was a sustained GFP expression in the retinas at 10 weeks post-injection. Examination of the whole retina before sectioning revealed that GFP fluorescence was not uniform, typically being much brighter in one quarter to one half of the retina, in the vicinity of the initial lower-temporal vector injection. Native GFP fluorescence levels revealed detectable variation between groups (Supplementary Figure 1) , and although these data provided no information about laminar or cellular location, overall, the comparative levels of GFP transduction for each serotype were consistent with subsequent quantitative histological analyses of retinal sections.
Transduction efficiencies of rAAV vectors: histological analysis
Two to five slides (10-12 retinal sections per slide) per animal in each rAAV serotype group (n ¼ 3-6 per group) were quantified. For all serotypes, there was some variation in the intensity of native GFP immunofluorescence in individual cells, and GFP immunohistochemistry was carried out on retinal sections from each group. Within each serotype group there was no significant difference in cell counts between immunostained and non-immunostained sections and data were therefore pooled. Consistent with the initial whole retina analysis, the extent of AAV transduction seen in retinal sections varied across the retina, with an average of 50-60% of retinal sections containing at least some GFP + cells. Retinas from rAAV2/2-and rAAV2/6-injected eyes contained the greatest number of transduced cells (that is, highest transduction efficiency), with an average of 1.9 and 1.7 cells per mm retinal section, respectively ( Figure 1 ). Transduction was lowest in rAAV2/5-and rAAV2/8-injected eyes. Statistical analysis revealed no significant difference between rAAV2/2 and rAAV2/6; however, rAAV2/2 GFP transduction was significantly higher than rAAV2/4 and rAAV2/8. rAAV2/6 transduction was also significantly greater than that found using rAAV2/8 vectors.
Cellular tropism of rAAV serotypes
Transduced retinal cells were identified on the basis of their laminar location, morphology and confirmed using cell-specific immunomarkers (Figures 2 and 3 ). With the exception of rAAV2/6, all rAAV serotypes preferentially transduced cells located within the RGC layer (Figures 2a  and 4 ). Calculated as a proportion of the total number of GFP + cells, between 57 and 71% were located in the RGC layer; however for rAAV2/6, only about 24% of transduced cells were found in this layer. Multiple group comparisons revealed that this value was significantly less than that found for rAAV2/2 and rAAV2/8 serotypes. GFP + cells in rAAV2/6-injected animals were mainly found in the inner nuclear layer (61%) (Figures 2e  and 4g ). Note that, even after intravitreal injection, rAAV2/3 and rAAV2/5 showed some tropism towards cells in the outer nuclear layer (Figures 2d, 4d and f) .
A further characterization of transduced (GFP + ) retinal cell types was based on cell morphology supported by immunostaining with various cell-specific markers 11 ( Figures 2, 3 and 5) . No allocation to a specific cell type was made unless clearly defined cell bodies and processes were distinguished; overall, 56% of GFP + cells were phenotyped. Of these characterized cells, RGCs constituted the highest proportion of transduced cells in six serotype groups (49-64%; Figure 5 ), but in the rAAV2/6 group, only 23% of transduced cells were RGCs ( Figure 5f ). As transduction efficiency was highest in the rAAV2/2 group, many GFP + axons were seen in the optic nerves of these animals ( Figure 2c ). Note here that the tropism results for rAAV2/2 were remarkably similar to data obtained in an earlier study using the same rAAV2/2 vector construct.
11 GFP + axons were also seen in the optic nerve of rAAV2/6-injected animals ( Figure 3g ) even though this vector displayed a much lower tropism for RGCs. In both vector groups, almost all GFP + axons exited from the temporal side of the retina, confirming more frequent transduction of RGCs in the vicinity of the initial intravitreal injection. rAAV2/8 displayed the highest degree of tropism for RGCs (Figure 5g ), but because of very low transduction efficiency in these eyes (Figure 1 ), the total number of transduced cells in inner retina in this group was low and far fewer than that seen using the rAAV2/2 vector serotype. 
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In both rAAV2/3-and rAAV2/5-injected eyes, over 20% of transduced cells were identified as photoreceptors (Figures 2d, 5c and e). However, overall rAAV2/3 transduction efficiency was about three times greater than that for rAAV2/5; thus the greatest number of GFP + photoreceptors was seen in the rAAV2/3-injected group. rAAV2/4 transduced relatively larger numbers of amacrine cells and Mü ller glia within the inner nuclear layer Figure 5 (a-g) The proportions of GFP + cells transduced for each serotype that could be identified on the basis of nuclear location and morphology, and characterization using immunomarkers. GFP, green fluorescent protein.
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M Hellström et al ( Figure 5d ). rAAV2/6 had the most diverse tropism profile among the tested vectors ( Figure 5f ); the majority of the transduced cells were amacrine cells (25%) and bipolar cells (21%; Figure 3b ), but a large number were also classified as Mü ller glia (22%; Figures 3c-e). Mü ller glia were only infrequently transduced by rAAV2/8 and rAAV2/5, at levels that were significantly lower than those seen in retinas from rAAV2/4-and rAAV2/6-injected eyes. Horizontal cells were only rarely transduced by any of the seven rAAV vectors tested in this study (Figures 3f and 5 ). For rAAV2/1-5 vectors, between 15 and 25% of the GFP + cells found in the RGC layer were not obviously immunoreactive for bIII-tubulin, and where a clear profile was seen these were counted as displaced amacrine cells. 28 Interestingly, these transduced bIII-tubulin À cells in the RGC layer were more frequent after rAAV2/6 or rAAV2/8 injection (43 and 45%, respectively), which at least for AAV2/6 was consistent with this vector's overall lack of transduction specificity ( Figure 5f ).
Discussion
This study compared the transduction efficiency of seven pseudoserotyped rAAV vectors after a single intravitreal injection into adult Wistar rat eyes. Vectors consisted of the AAV2 backbone cross-packed into the capsids from AAV serotype 1-6 or AAV8. Earlier investigations that compared the transduction efficiency of rAAV serotypes in the eye used in vivo fluorescent imaging, fundus luminescence quantification, and in some studies, quantitative PCR. 3, 4, [6] [7] [8] 12 Quantitative analysis of immunostained retinal sections has been carried out after intravitreal rAAV2/2 injections, 11 but to our knowledge, this type of analysis has not been used to compare the transduction efficiency and tropism of different rAAV serotypes after injection into the vitreous.
When analyzed 10 weeks after a single titre-matched intravitreal injection, we here confirm earlier tropism and transduction findings for rAAV2/2 11 and report new data on six additional rAAV vectors. Measurement of native GFP expression in whole retina before sectioning revealed between-group differences in fluorescence levels that were largely consistent with subsequent GFP + cell counts in cryosectioned material. rAAV2/2 and rAAV2/6 displayed the highest transduction efficiency, followed by rAAV2/3. rAAV2/5 and rAAV2/8 were the least efficient. rAAV2/6 had the most diverse tropism profile, transducing many neuronal cell types as well as Mü ller glia. These retinal glia were also relatively more frequently transduced by rAAV2/4. Apart from rAAV2/6, all other vectors transduced RGCs more frequently than other cells, but because of greater transduction efficiency, the highest number of GFP + RGCs and axons was seen after rAAV2/2 injections. With this vector, about two-thirds of all transduced cells were RGCs. Following rAAV2/3 or rAAV2/5 injection, 20-25% of GFP + cells were photoreceptors; however, the total number of these cells was greatest in the rAAV2/3 group, again due to relatively greater transduction efficiency.
For all vector groups, there was some interanimal variability in the spatial extent of GFP expression across the retina, but GFP + cells were usually most frequently encountered in ventral and temporal retina, in the vicinity of the original intravitreal injection. In this regard, note that the transduction efficiency data presented here were obtained from sections sampled across the entire retina, contributing to the apparently low average number of GFP + cells per mm of retinal section. Nonetheless, for rAAV2/2 at least, when encoding the appropriate transgene, this level of transduction is sufficient to significantly enhance the survival and regeneration of injured RGCs. 9 The localized nature of rAAV retinal transduction after a single 4 ml intravitreal injection suggests that a more homogeneous transduction (and perhaps even better functional outcomes) may be achieved by using multiple injections and larger injection volumes, perhaps carried out sequentially over a period of days. In this context, vector transfer in combination with specific epidermal growth factor receptor protein tyrosine kinase inhibitors or with proteasome inhibitors may also result in higher transduction efficiency in ocular gene therapy. 32, 33 Of course, increased transduction and stronger transgene expression from gene therapy applications may not necessarily lead to better outcomes, and there is likely to be a fine balance between therapeutic and detrimental expression levels, especially for genes that encode secretable proteins. [34] [35] [36] This should also be taken into account when choosing promoters that may increase the specificity of transgene expression [37] [38] [39] and when designing vector systems that allow the temporal regulation of transgene expression. [40] [41] [42] [43] Although comparable in terms of overall transduction efficiency, the tropism profile between rAAV2/2 and rAAV2/6 was considerably different. AAV2 and AAV6 share 82% homology and differ by 53 amino acids in the variable region of the Cap gene. 21 AAV2 is known to enter cells through the heparin sulphate proteoglycan receptor, fibroblast growth factor receptor 1 and the integrin receptors aVb1 and aVb5. [44] [45] [46] [47] A laminin receptor has also been implicated for AAV2 cell entry.
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AAV6 can also bind to heparin sulphate proteoglycan receptors, 49, 50 but unlike AAV2, AAV6 is not inhibited by soluble heparin. 51 Instead, AAV6 has been shown to be dependent on cell-bound sialic compounds presented on N-linked glycoproteins. 52 These different vector-cell interaction characteristics may cause the profile divergence seen between rAAV2/2 and rAAV2/6 in this study. Interestingly, AAV6 and AAV1 share 99% sequence similarity in the VP1 capsid genome. 19 Nonetheless, the vector carrying the rAAV1 capsid transduced very few cells in this experiment. Cell entry is not the only obstacle in vector transduction, the intracellular trafficking is also known to be a limiting factor 53 and may explain the poor outcomes seen here with rAAV2/1. Interpretation is also complicated by the fact that the process of injecting rAAV into the vitreous will rapidly alter the expression of growth factors and some receptors such as fibroblast growth factor receptor 1, 54 potentially influencing the types of cell transduced by rAAV vectors. rAAV2/3 was the third most efficient vector tested in this experiment and over 20% of transduced cells were photoreceptors. Other serotypes delivered intravitreally were less effective in transducing these outer retinal neurons. This tropism was unexpected due to generally Transduction properties of AAV vectors in retina M Hellström et al poor diffusion of rAAV vectors across the retina after intravitreal delivery and because rAAV2/3 has not been shown to be efficient when applied subretinally. 6 The majority of cells in the retina are photoreceptors and desired vectors for the treatment of photoreceptorassociated disorders will need high transduction efficiencies. However, the levels of transduction seen for rAAV2/3 may be sufficient if the vector encodes secretable factors. Intravitreal injections for the treatment of photoreceptor dysfunction may have advantages, including capacity for larger, as well as multiple, vector injections and possible combinations with other pharmacotherapeutic agents. 9, 10, [27] [28] [29] [30] [31] In our hands, rAAV2/1, rAAV2/4, rAAV2/5 and rAAV2/8 were the least efficient among the tested vectors. Earlier studies based on fluorescent intensity measurements have also shown low transduction efficiencies for these vector types; 4, 7, 8, 12 however, when injected subretinally, others have reported that rAAV2/ 8 is efficient, even for transducing RGCs. 4 The authors speculated that, in contrast to the other vectors tested, the rAAV2/8 vector may have been transited from transduced photoreceptor cells to other neurons in the visual pathway because they also reported poor RGC transduction after an intravitreal injection. 4 Interestingly, for rAAV2/2 at least, although this vector remains the most effective for targeting RGCs after intravitreal injection into adult eyes, the transduction profile varies significantly depending on the age of the injected animal. Thus, after intravitreal rAAV2/2 injection into neonatal eyes, about two-thirds of the GFP + cells are found in the photoreceptor layer and a more adult-like pattern is established by 2 weeks after birth.
11
It is important to continuously evaluate novel rAAV vectors for human gene therapy as a large proportion of the human population carry sera with neutralizing antibodies against many different AAV serotypes. 25, 55 Our quantitative serotype data in adult eyes provide new information on transduction and cellular tropism characteristics of different rAAV vectors that may aid in the development of improved protocols for the treatment of many types of retinal disease. RGC loss is a feature of many degenerative ophthalmic conditions, 28 and there is also ongoing, often aberrant, remodelling of intraretinal circuitry as a consequence of photoreceptor loss. 56, 57 Use of appropriate AAV vectors may prevent or reduce such anomalous reorganizations within the inner nuclear layer, potentially enhancing the effectiveness of other therapies such as cellular or bionic implants. 57 Finally, new vector constructs, different modes of delivery, 24, 25 and the isolation and modification of different serotypes 7,58-62 will lead to novel vectors that have greater packaging capacity 33, 63 and cell specificity, and may even further minimize immunological sequelae following therapeutic application.
Materials and methods
Vector production and purification AAV vectors were generated using the plasmid pTRCGW. 64 This plasmid harbours a transgene expression cassette that contains the human cytomegalovirus promoter, a cDNA encoding GFP, a polyadenylation (polyA) signal and the woodchuck post-transcriptional regulatory element. The transgene expression cassette is flanked by the AAV2 inverted terminal repeats. Helper plasmids used for cross-packaging were generously provided by Dr Kleinsmidt (University of Heidelberg, Germany) and used as described earlier. 65 Briefly, pTRCGW (50 mg per roller bottle) and the helper plasmids (ratio 1:3) were co-transfected into 293T cells cultured in roller bottles (850 cm 2 surface, Greiner, Alphen aan Den Rijn, The Netherlands) using calcium phosphate. Each roller bottle contained 2.5 Â 10 7 cells. Cells were grown in 50 ml of Iscove's modified Eagle's medium without phenol red and pyruvate, and supplemented with 10% fetal calf serum and pen/strep (Invitrogen, Breda, The Netherlands). Medium was refreshed 2 h before and on the day of transfection. Recombinant AAV was harvested 66 h post-transfection by removing the medium and adding 5 ml of lysis buffer (50 mM Tris (pH 8.5), 2 mM MgCl, 150 mM NaCl and 0.1 % Triton X-100) per roller bottle. The lysis buffer from roller bottles was pooled and incubated for 1 h with 10 mg ml À1 DNAse. This harvest was spun down (30 min, 4000 g) and filtered through a 0.45-mm 2 mesh filter.
AAV serotypes 1, 2, 3 and 5 were purified using affinity chromatography with AVB Sepharose High Performance (GE Healthcare Bio-Sciences AB, Brussels, Belgium). After loading the column with crude lysate, the column was rinsed with 10 column volumes of 0.1 M Tris-HCl, pH 8.5, and eluted in DPBS (Invitrogen), pH 3.5. For neutralization to pH 7.4, the eluate was collected in 10% v/v 0.1 M Tris, pH 8.5. A buffer change was performed in Amicon Ultra-15 (Millipore, Billerica, MA, USA) concentrators to DPBS (pH 7.4) supplemented with 5% sucrose, and the rAAV vector was concentrated to the appropriate volume.
AAV serotypes 4, 6 and 8 were isolated on an iodixanol density gradient. Crude lysate (18.5 ml) was underlayered with 9 ml 15%, 5 ml 25%, 5 ml 40% and 3 ml 60% iodixanol (Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS), pH 7.4, supplemented with 10 mM MgCl 2 and 25 mM KCl. Centrifugation was performed for 1 h 10 min in a 70Ti Beckman rotor at 69 000 r.p.m. at 16 1C. The viral vector will concentrate between the 40 and 60% iodixanol bands. Approximately 5 ml was collected by puncturing the centrifuge tube with a syringe. Before concentrating in an Amicon Ultra-15 concentrator, rAAV was diluted 1:1 in DPBS to reduce the viscosity of the iodixanol solution. At least three volumes of DPBS were spun through the filter device before the vector stock was spun down with two volumes of DPBS supplemented with 5% sucrose. All vector stocks were kept at À80 1C until use.
Characterization of purified rAAV stocks included quantitative PCR analysis to determine the number of genomic copies (GCs), SDS-polyacrylamide gel electrophoresis analysis for visualization of the three capsid proteins 65 and an infection assay of 293T cells to verify the infectivity. The infection assay was performed using serial dilutions of the vector, by adding the viral vector to camptothecin-treated (4.8 mg ml À1 for 4 h) 293T cells. The presence of transduced cells was determined at 3 days post-infection under a fluorescence microscope. GC titres were in the range of 6.6 Â 10 11 to 1.5 Â 10 12 GC ml
À1
. Before intravitreal injection, all AAV vector stocks were titre matched at 6.6 Â 10 11 GC ml
. 
Eye injections
Intravitreal eye injections were carried out as described earlier. [9] [10] [11] In anaesthetized rats (1-1.5 ml kg À1 i.p. of a 1:1 mixture of ketamine (100 mg ml
À1
) and xylazine (20 mg ml À1 )), rAAV was injected into the vitreous through a glass micropipette inserted into peripheral lower temporal retina. Each animal (n ¼ 6 per rAAV serotype) received a total injection volume of 4 ml titrematched rAAV vector equivalent to 2.6 Â 10 9 GC per injection. Rats were killed 10 weeks post-injection.
Tissue processing and native GFP fluorescence measurements
Animals were overdosed with an i.p. injection of Lethabarb (sodium pentobarbitone) and were perfused with PBS (pH 7.4) containing 0.1% heparin followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Both eyes were removed, the cornea and lens cut away and retinas were post-fixed in the eyecups for 1 h. Before cryosectioning, native GFP fluorescence was visualized in the eyecup from most of the rAAV-injected animals (Kodak imager 2000MM; excitation, 465 nm; emission, 535 nm; 1 min exposure). On the retrieved image, a circle was drawn (circle area ¼ 2044 pixels) and placed in the centre of each eyecup. Intensity levels were recorded with Adobe Photoshop (CS2) histogram function. For each animal, the fluorescence of the non-injected eye was also recorded to establish a baseline fluorescence level. Eyecups and optic nerves were then cryoprotected in Jung freezing medium (Leica, Sydney, Australia) and frozen at À25 1C and put in À80 1C until further processing. Cryostat sections (16 mm) were cut horizontally through the eyecup from ventral to dorsal side so that each section contained a complete temporal-to-nasal cross-section of the retina. Every third section was collected in a series of 10 slides with 10-12 sections per slide, thus each slide sampled sections from across the entire retina. Slides were stored at À20 1C.
Immunohistochemistry
After removal from the freezer, slides were air-dried for 30 min at room temperature and rehydrated for 5 min in PBS before being blocked for 60 min with PBS buffer containing either 0.2% Triton X-100 and 10% normal goat serum or 5% horse serum plus 2% bovine serum albumin. Depending on the source of the secondary antibody, antibodies were diluted in one or the other of these blocking solutions. Selected slides were stained with a primary rabbit or mouse anti-GFP antibody (1:100; Millipore, Sydney, Australia), followed by an appropriate fluorescein isothiocyanate-conjugated secondary antibody (1:100; Sigma), to assure that a weak native GFP fluorescence was not overlooked in the analysis. Antibodies used for GFP + cell characterization were mouse anti-bIII-tubulin (RGCs; 9, 66 1:5000; Swant, Bellinzona, Switzerland), overnight at +4 1C, followed by 3 Â 5 min washes in PBS. Sections were then incubated for 1 h with an anti-mouse or anti-rabbit Cy3-conjugated secondary antibody (1:300; Jackson, West Grove, PA, USA), rinsed for 3 Â 5 min in PBS before being coverslipped with Dako fluorescent mounting media containing Hoechst 33342 (Sigma) nuclear dye.
Quantification methods and phenotype-identification procedures
After examination of sectioned material, four retinas were excluded from further analysis because it was clear that the initial injection procedure had damaged posterior retina and that some vector had been delivered directly into retinal tissue. In the remaining 38 animals, all retinal sections on selected slides were examined and GFP + cells were counted. Quantification, localization and phenotype analysis were performed at Â 400 using a fluorescent microscope (Nikon). Sections were also photographed at Â 20 and the length of each section measured along the inner retinal surface (Image-Pro Express software; Media Cybernetics). The number of transduced cells was divided by the total retinal length per animal and averaged for each serotype tested. GFP + cells were counted and documented according to the retinal layer in which they were found. Characterization of transduced (GFP + ) retinal cell types was based on laminar location and morphology, and was confirmed using various cell-specific immunomarkers. 11 No counts were made unless a clearly defined cell body could be distinguished. GFP + non-neuronal Mü ller cells were included in a separate group.
Statistical analysis
For each rAAV serotype, the number of identified cells and the total length of analyzed retina were determined, allowing a calculation of the number of transduced cells per mm retina per animal. The mean and standard error of the mean (s.e.m., error bars in all graphs) were calculated and significance tested using one-way analysis of variance and post hoc Bonferroni and/or KruskallWallis tests (significance level Po0.05).
